Healthcare Products & Distribution / Medical Supplies Manufacturing
Strategic Profile
Through two primary segments—Medline Brand and Supply Chain Solutions—the company offers approximately 335,000 med-surg products including surgical and procedural kits, gloves and protective apparel, urological and incontinence care products, wound care solutions, and consumable laboratory and diagnostic items. Medline operates around 26 manufacturing facilities across North America, allowing the company to control product specifications, make quick adjustments, and scale new products faster, resulting in lower costs and reduced supplier dependency.
Cyborg Score Rationale
As the largest med-surg provider globally with diversified product portfolio across surgical, front-line care, and diagnostics. Medline boasts a high customer retention rate of over 98% as a primary vendor for many healthcare systems. Strong analyst sentiment with multiple Buy ratings post-IPO supports the outlook.
Top Insights
Record-setting $6.26B IPO completed in December 2025 with strong post-IPO performance, allocating proceeds to debt reduction from 2021 leveraged buyout.
According to 23 analysts, the average rating for MDLN stock is "Strong Buy" with 12-month stock price target of $47.74, representing 7.16% upside from current levels.
Approximately 50% of revenue comes from the Medline Brand segment with over 190,000 proprietary items, providing higher margin and stickier revenue.
Company is majority-owned by private equity firms Blackstone, Carlyle, and Hellman & Friedman, providing experienced operational ownership and strategic guidance.
Named Competitors
McKesson Healthcare — Large-scale healthcare and pharmaceutical distribution
Cardinal Health — Healthcare supplies and medical products distribution
Henry Schein — Dental and medical supplies provider
Baxter — Medical devices and healthcare solutions
Recent Developments
(December 2025) Completed record-setting $6.26B IPO, largest IPO of 2025, raising capital to reduce debt from 2021 leveraged buyout
(December 2025) Stock surged 41% above $29 offer price on first trading day, closing at $41 and giving company ~$54B market valuation
(January 2026) Multiple major investment banks initiated MDLN coverage with Buy ratings including Citi, TD Cowen, BTIG, and Mizuho
(February 2026) Scheduled to report full year 2025 and Q4 results on February 25, 2026
Open the full interactive Medline Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.